Autonomix Medical, Inc.AMIXEarnings & Financial Report
Autonomix Medical, Inc. is a medical technology firm that develops innovative minimally invasive diagnostic and therapeutic devices focused on cardiac electrophysiology applications. Its core offerings target improved detection and treatment of cardiac arrhythmias, serving healthcare providers and patients across North American and European healthcare markets, with a key focus on advancing care for rhythm-related heart conditions.
AMIX Q3 FY2026 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-3.3M
Net Profit
$-3.3M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.36
Autonomix Medical, Inc. Q3 FY2026 Financial Summary
Autonomix Medical, Inc. reported revenue of $0 for Q3 FY2026, with a net profit of $-3.3M (down 20.2% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-3.3M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2026 |
Autonomix Medical, Inc. Annual Revenue by Year
Autonomix Medical, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
Autonomix Medical, Inc. Quarterly Revenue & Net Profit History
Autonomix Medical, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2026 | $0 | — | $-3.3M | N/A |
| Q2 FY2026 | $0 | — | $-7.5M | N/A |
| Q1 FY2026 | $0 | — | $-3.3M | N/A |
| Q4 FY2025 | $0 | — | $-3.2M | N/A |
| Q3 FY2025 | $0 | — | $-2.7M | N/A |
| Q2 FY2025 | $0 | — | $-2.8M | N/A |
| Q1 FY2025 | $0 | — | $-2.7M | N/A |
| Q3 FY2024 | $0 | — | $-3.1M | N/A |
Income Statement
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.8M | $7.1M | $5.4M | $12.0M | $9.8M | $9.0M | $7.9M | $10.2M |
| Liabilities | $7.4M | $1.8M | $2.3M | $2.2M | $1.7M | $2.0M | $1.5M | $1.6M |
| Equity | $-5.6M | $5.3M | $3.0M | $9.7M | $8.1M | $7.0M | $6.4M | $8.6M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-1.9M | $-1.6M | $-2.3M | $-2.6M | $-2.6M | $-3.8M | $-3.0M |